Israel’s Teva Pharmaceuticals will start to distribute a medical cannabis inhaler developed by Syqe, an Israeli start-up that raised money from tobacco giant Philip Morris. The inhaler may also be tested with opiates.

An editorial in The Scientist says its unacceptable that the World Health Organization has not developed positions on legalization.

Toronto’s Hospital for Sick Children will begin a clinical trial of cannabis extracts containing CBD and THC for children with severe epilepsy.

A new study from Steep Hill Labs found that 83 percent of California weed wouldn’t pass Oregon’s testing standards. An industry report says Oregon’s strict regulations are crushing the state industry. Willamette Week reports that business conditions are pushing some entrepreneurs back to the underground market.

Rehab provider Spectrum Health Systems said a doctor was not to blame for revealing to a patient’s employer that she uses MED.

A survey of cannabis researchers finds out what they want from the government in order to pursue their work.

A Reason investigation finds that conservative authorities in Idaho “conspired to restrict a promising cannabis-derived seizure treatment.”

The National Fire Protection Association is developing fire safety standards for cannabis businesses.

The FDA will allow a late stage clinical trial for ecstasy as a treatment for PTSD.

Minnessota approved PTSD as a MED qualifying condition. New York approved chronic pain.

Canada’s legalization push is getting complicated. The much-anticipated task force report on legalizationhas been delayed. Meanwhile activists wonder why shops are getting raided if the government plans to legalize. For more see here.

Bill Blair a Canadian government official overseeing the issue appeared at a “ cash-for-access” fundraiser with cannabiz leaders that may have violated Liberal Party ethics guidelines. Blair defended recent raidssaying, “The only system for control is the existing legal regime. And we’re a society of laws,” he says.

It would be the first in the country.

Here’s your daily round-up of pot-news, excerpted from the newsletter WeedWeek. 

Denver’s social use initiative is in the lead with some ballots still uncounted. If approved it would be allow bars and other businesses to apply for on-site pot consumption permits.

After Election Day, there are now eight more Senators and 68 more members of the House representing REC states, and six more Senators and 33 more members representing MED states. Marijuana.com predicts that it will be harder for them to reject cannabis reform legislation out of hand.

Massachusetts treasurer Deb Goldberg says she may need an extension of the October 2017 deadline to begin accepting license applications. Additional tweaks on taxes, edibles and DUI are anticipated.

How Florida’s MED program will work remains hazy.

Marijuana Business Daily calls it an $8 billion-night based on the combined annual sales projected in the newly legal states. Vox explains the votes. The New York Times has a round-up.

Rob Sands, CEO of Constellation Brands, whose portfolio includes Svedka Vodka and Robert Mondavi wine, said the company is interested in going green. “There are going to be alcoholic beverages that will also contain cannabis.”

The New York Stock Exchange accepted cannabis real estate investment trust (REIT) Innovative Industrial Properties’ listing. It will be the first cannabis REIT to trade on the exchange. It’s ticker will be IIPR.

Canadian producer Aphria announced a C$35M raise, the largest by a public company to date. Legal Canadian growers have raised more than C$313M in the last 13 months.

The New York Times profiles Denver-based Dixie Brands as it builds a national presence.  (For more on interstate trade, see my April story in The Washington Post.)

WIRED tells us to “Get ready for the Budweiser of bud.”

Adrian Sedlin, CEO of California grower CannDescent, told Fortune that leaving California companies without bank accounts is “ not a tenable position.”

LAWeekly finds some psyched local cannabis executives. The San Jose Mercury News talks to some pumped-up Investors.

An interesting finding

Here’s your daily round up of pot news, excerpted from the newsletter WeedWeek.

The Centers for Disease Control found that more Americans are using cannabis but the abuse rate has fallen. For additional details see here.

At the L.A. Times, Robin Abcarian looks at the links between cannabis use and psychosis.

A study found that being high decreases cannabis users’ motivation, but that it returned when they were sober.

The DEA said it would add the psychotropic tropical plant kratom, which some consider to have health benefits, to its list of schedule I substances, alongside LSD, heroin, cannabis and other drugs it considers to have no medical uses.

Israeli doctors will begin a first of its kind study to test the effects of cannabis on individuals with autism. The country also plans to start exporting MED.

New York state will expand its MED program, and allow home delivery. Crain’s New York Business asks if the state will allow the industry to thrive. Oregon licensed its first two testing labs.

This month, a Manhattan gallery owner known as Mr. Grey will host an exhibit of bongs valued between $500 and $250,000. You can see pieces from his collection on his Instagram page.

The Forward has a “ Pot Shabbat” with “Jeff the 420 Chef.” The challah, matzo balls, Brussels sprouts, potatoes and cookies were all laced.

Vice meets an Englishman who legally changed his name to “ Free Cannabis.” He planted cannabis in Glastonbury’s celebrated flower displays.

A new cannabis social network caters to seniors. Jimi Hendrix is enshrined in a new line of edibles.

The great comedian Gene Wilder died. Though it did not make the connection, The Cannabist reviewed Snozzberry, an indica dominant hybrid, named for a fruit invented by Willy Wonka. Wilder also appears to smoke weed in “Blazing Saddles.”